Structure Therapeutics Inc.
GPCR$4.30B
Mid CapNASDAQBiotechnology🇺🇸North America218 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jul 15, 2026
17wMarket Overview
Stock performance and key metrics
GPCR News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
GSBR-1290
Overweight or Obesity
Aleniglipron
Obesity, Overweight, or Chronic Weight Management
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GSBR-1290 | Phase 2 | Overweight or Obesity | - | - |
Aleniglipron | Phase 2 | Obesity, Overweight, or Chronic Weight Management | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply